|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:disease
gptkb:2014
gptkb:FDA
gptkb:Oncology
|
|
gptkbp:available_in
|
vial form
|
|
gptkbp:brand
|
gptkb:Opdivo
|
|
gptkbp:can_be_combined_with
|
gptkb:ipilimumab
chemotherapy
|
|
gptkbp:clinical_trial
|
gptkb:Check_Mate_trials
Phase 1
Phase 2
Phase 3
|
|
gptkbp:clinical_use
|
palliative care
adjuvant therapy
neoadjuvant therapy
first-line therapy
second-line therapy
|
|
gptkbp:contraindication
|
autoimmune diseases
hypersensitivity to nivolumab
organ transplant history
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:dosage_form
|
solution for infusion
every 2 to 4 weeks
|
|
gptkbp:effective_date
|
gptkb:2014
|
|
gptkbp:healthcare
|
gptkb:2014
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Opdivo
|
|
gptkbp:indication
|
gptkb:disease
gptkb:hepatocellular_carcinoma
gptkb:Oncology
esophageal cancer
small cell lung cancer
head and neck cancer
|
|
gptkbp:invention
|
gptkb:Bristol-Myers_Squibb
2028
|
|
gptkbp:is_monitored_by
|
liver function tests
thyroid function tests
renal function tests
|
|
gptkbp:marketed_as
|
gptkb:nivolumab
gptkb:Bristol-Myers_Squibb
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
immune checkpoint inhibitor
PD-1 inhibitor
|
|
gptkbp:patient_population
|
adults
pediatric patients (under investigation)
|
|
gptkbp:pharmacokinetics
|
half-life of approximately 26 days
increases T-cell activity
decreases tumor growth
|
|
gptkbp:previous_name
|
gptkb:nivolumab
|
|
gptkbp:price
|
high cost
|
|
gptkbp:reimbursement
|
covered by most insurance plans
|
|
gptkbp:research_focus
|
gptkb:immunotherapy
oncology
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety_features
|
generally well tolerated
risk of severe immune reactions
|
|
gptkbp:sales
|
$7 billion (2020)
|
|
gptkbp:service_frequency
|
every 2 to 4 weeks
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
immune-related adverse events
|
|
gptkbp:storage
|
refrigerated
2 to 8 ° C
|
|
gptkbp:symbolism
|
gptkb:2015
|
|
gptkbp:targets
|
gptkb:PD-1
|
|
gptkbp:treatment
|
gptkb:Yervoy
chemotherapy
targeted therapy
|
|
gptkbp:used_for
|
treatment of cancer
|
|
gptkbp:wholisting
|
Essential Medicines List
|
|
gptkbp:bfsParent
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:bfsLayer
|
4
|